KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint.

Jean-Frederic Colombel, Jianmin Wu, Taku Kobayashi, Baojin Zhu, Jerome Paulissen, Agni Dhanabal, Vipul Jairath, Corey Siegel, Britta Siegmund, Isabel Redondo, Richard Moses, Fernando Magro

J Crohns Colitis 19(9) jjaf124

PMID40651005
PMCIDPMC12561001
DOI10.1093/ecco-jcc/jjaf124
发表日期2025-07-12
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:AI 判定为 other。
摘要

摘要

BACKGROUND AND AIMS: Concurrent achievement of symptomatic, endoscopic, and histologic remission, known as disease clearance, has been proposed as a treatment target in ulcerative colitis. Mirikizumab, an anti-interleukin-23p19 antibody, has demonstrated long-term efficacy and safety, as reported in the LUCENT Phase 3 trials (NCT03518086, NCT03524092, and NCT03519945). The current analysis evaluates the impact of mirikizumab on disease clearance and its association with other clinical and patient-reported outcomes (PROs). METHODS: LUCENT methods have previously been reported. The proportion of patients achieving disease clearance was determined through week (W)104. Association analyses were assessed between disease clearance and PROs (IBDQ, SF-36, WPAI: UC, PGRS, and PGRC), and early disease clearance and subsequent clinical outcomes (clinical, corticosteroid-free, endoscopic, histological, histologic-endoscopic, bowel urgency, stool frequency, and rectal bleeding). RESULTS: The proportions of patients achieving disease clearance with mirikizumab at W12, W52, and W104 were 16.0%, 36.4%, and 51.3%, respectively. Mirikizumab-treated patients with disease clearance showed greater PRO improvements through W52 than those without. Early clearance at W12 was associated with significantly better clinical outcomes at later time points, except for bowel urgency remission at W52. This trend was repeated for clinical outcomes at W104 in patients who achieved disease clearance at W52. CONCLUSIONS: Mirikizumab consistently demonstrated disease clearance across induction, maintenance, and long-term studies. The attainment of disease clearance was associated with greater improvement in PROs, and early achievement of disease clearance was associated with better long-term outcomes, including clinical remission, corticosteroid-free remission, endoscopic and histological outcomes, reduced stool frequency, and rectal bleeding.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. (A) The proportion of patients achieving DC at W12 in LUCENT-1. (B) The proportion of patients achieving DC at W40 in LUCENT-2 (52-week treatment in total). (C) Proportion of patients achieving DC at W104 among patients who achieved clinical remission at W52 and subsequently entered the LUCENT-3. a 5 patients receiving PBO and 15 patients receiving MIRI were previously exposed to but had no biologic or JAK inhibitor failure and were excluded from the biologic subgroup analysis. b 1 patient receiving PBO and 8 patients receiving MIRI were previously exposed to but had no biologic or JAK inhibitor failure and were excluded from biologic subgroup analysis. c 5 patients were previously exposed to but had no biologic or JAK inhibitor failure and were excluded from the biologic subgroup analysis. DC = symptomatic remission + histologic-endoscopic mucosal remission. DC, disease clearance; JAK, Janus kinase; MIRI, mirikizumab; NRI, nonresponder imputation; PBO, placebo; W, Week.
非 KM Figure
Figure 2Figure 2. Association between achievement of DC and patient-reported outcomes in mirikizumab-treated patients; fatigue NRS (a), IBDQ remission (B), SF-36 PCS (C), SF-36 MCS (D), WPAI: UC overall work productivity (E), PGRS (F), and PGRC (G) at W12 and W52. DC, disease clearance; IBDQ, inflammatory bowel disease questionnaire; LSM, least-squares mean; MCS, mental component summary; N, no; NRS, numeric rating scale; PCS, physical component summary; PGRC, patient global rating of change; PGRS, patient global rating of severity; SF-36, 36-item short form health survey; UC, ulcerative colitis; WPAI, work productivity and activity impairment questionnaire.
非 KM Figure